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Arteriovenous Fistula to Prevent
Venous Stenosis Formation
Rajiv Janardhanan, PhD, Binxia Yang, MD, PhD, Sreenivasulu Kilari, PhD,
Edward B. Leof, PhD, Debabrata Mukhopadhyay, PhD,
and Sanjay Misra, MDABSTRACT
Purpose: To determine if a second dose of a lentivirus mediated small hairpin RNA that inhibits Vegf-A gene expression (LV-
shRNA-Vegf-A) can improve lumen vessel area (LVA) of the outﬂow vein of an arteriovenous ﬁstula (AVF) and decrease
venous neointimal hyperplasia.
Materials and Methods: Chronic kidney disease was created in C57BL/6 mice; 28 days later, an AVF was created by
connecting the right carotid artery to the ipsilateral jugular vein. Immediately after AVF creation, 5  106 plaque-forming units
of LV-shRNA-Vegf-A or control shRNA was administered to the adventitia of the outﬂow vein, and a second dose of the same
treatment was administered 14 days later. Animals were sacriﬁced at 21 days, 28 days, and 42 days after AVF creation for
reverse transcription polymerase chain reaction and histomorphometric analyses.
Results: By day 21, there was a 125% increase in the average LVA (day 21, P ¼ .11), with a decrease in cell proliferation (day
21, P ¼ .0079; day 28, P ¼ .28; day 42, P ¼ .5), decrease in α-smooth muscle cell actin staining (day 21, Po .0001; day 28, Po
.05; day 42, P ¼ .59), and decrease in hypoxic stress (day 21, P o .001; day 28, P ¼ .28; day 42, P ¼ .46) in LV versus control
shRNA vessels.
Conclusions: A second dose of LV-shRNA-Vegf-A administration results in a moderate improvement in LVA at day 21.
ABBREVIATIONS
αSMA = α-smooth muscle actin, AVF = arteriovenous ﬁstula, LV = lentivirus, LVA = lumen vessel area, RT-PCR = reverse
transcription polymerase chain reaction, shRNA = small hairpin RNA, TUNEL = terminal deoxynucleotidyl transferase dUTP nick
end labeling, VNH = venous neointimal hyperplasia& SIR, 2016. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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access for hemodialysis, and maintaining its function is
required for adequate hemodialysis. At 1 year, approx-
imately 38% of AVFs fail because of venous ste-
nosis formation, which is caused by venous neointimal
hyperplasia (VNH) (1). Histologic analysis of VNH
shows angiogenesis localized to the neointima and ad-
ventitia (2). This angiogenesis is accompanied by increa-
sed proliferation of cells staining positive for α-smooth
muscle actin (α-SMA) in the neointima (2). A recent
study demonstrated that transduction of a lentivirus
mediated small hairpin RNA that inhibits Vegf-A gene
expression (LV-shRNA-Vegf-A) to the adventitia of the
outﬂow vein immediately after AVF creation led to an
increase in lumen vessel area (LVA) compared with the
Volume 27 ’ Number 4 ’ April ’ 2016 577outﬂow veins transduced with control shRNA. More-
over, ﬁbroblast to myoﬁbroblast differentiation along
with a reduction in constrictive vascular remodeling
was observed in outﬂow veins of AVFs transduced
with Vegf-A shRNA (3). However, VNH started to
recur 2 weeks after Vegf-A shRNA administration to the
outﬂow veins of AVFs (3).
The aim of the present study is to determine whether
two doses of LV-shRNA-Vegf-A could improve LVA
and decrease VNH. Experiments were performed in a
murine model of chronic kidney disease with AVF. The
readouts were gene expression for Vegf-A, matrix metal-
loproteinase-2 (Mmp-2) and matrix metalloproteinase-9
(Mmp-9), proliferation, apoptosis, smooth muscle, and
Hypoxyprobe (Hypoxyprobe, Inc, Burlington, Massa-
chusetts) staining with histomorphometric analyses.MATERIALS AND METHODS
Experimental Animals
Approval of the Institutional Animal Care and Use
Committee was obtained before conducting any experi-
ments. The animals were housed and handled in accordance
with the Public Health Service Policy on Humane Care and
Use of Laboratory Animals (4) (revised in 2000). C57BL/6
male mice (Jackson Laboratories, Bar Harbor, Maine)
weighing 25–30 g were used for the study. The mice wereFigure 1. (a–c) Schematic of the study. BUN ¼ blood urea nitrogen. (A
reduces venous stenosis formation in a murine hemodialysis vasculamaintained at room temperature of 221C with 41% relative
humidity and 12-hour/12-hour light/dark cycles. The
animals were allowed access to water and food ad libitum.
Anesthesia was obtained using a combination of ket-
amine hydrochloride (0.1–0.2 mg/g) and xylazine (0.02
mg/g), which was administered using intraperitoneal
delivery, and further anesthesia was maintained using a
combination of ketamine hydrochloride (0.02 mg/g) and
xylazine (0.002 mg/g), intraperitoneal delivery. All sur-
gical procedures were performed by B.Y. Chronic renal
insufﬁciency was created by performing a nephrectomy of
the right kidney combined with ligation of the upper polar
branch of the renal artery to the left kidney (5). In this
model, after this procedure, the average blood urea
nitrogen and creatinine are signiﬁcantly elevated 28 days
later (5). A carotid artery–to–jugular vein AVF was
created 4 weeks later (Fig 1a–c) (5,6). The shRNA for
Vegf-A was purchased from Open Biosystems, Inc
(Huntsville, Alabama) and was prepared according to
the manufacturer’s protocol (7). At the time of AVF
creation, 5  106 particle-forming units of either LV-
shRNA-Vegf-A or scrambled-shRNA (control shRNA,
nontargeting empty vector) in 5 μL of phosphate-buffered
saline was administered to the adventitia of the proximal
outﬂow vein using a 30-gauge needle. The same therapy
was repeated 14 days later using a separate surgical
procedure (8). Previously, experiments conducted using
this technique showed that venous stenosis forms in thisdapted from Janardhanan R, Yang B, Vohra P, et al. Simvastatin
r access model. Kidney Int 2013; 84:338–352 [10].)
Janardhanan et al ’ JVIR578 ’ Repeat Adventitial Transductionmodel at the outﬂow vein (5–7,9–11). Nephrectomy was
performed in 79 male C57BL/6 mice weighing 25–30 g.
One mouse died after nephrectomy. Six mice were
excluded because a ﬁstula could not be placed as a result
of arterial thickening and inﬂammation. Animals were
sacriﬁced at day 21, day 28, and day 42 after placement of
the AVF for reverse transcription polymerase chain
reaction (RT-PCR) and histomorphometric analyses at
each time point (Fig 1a).
Tissue Harvesting
Before sacriﬁce, the mice were anesthetized as described
previously. Next, the ﬁstula was dissected free of any
surrounding tissue. Patency of the ﬁstula was assessed at
the time of harvesting the tissue by gently obstructing the
outﬂow vein and assessing if the vein proximally dilated,
which was recorded as patent. Carbon dioxide asphyx-
iation was used, and the outﬂow veins were harvested for
RT-PCR or histologic analyses. The vessels were perfu-
sion ﬁxed before removal for histologic analysis (7).
RNA Isolation and RT-PCR Analysis
The tissue was stored in RNA stabilizing reagent (Qiagen,
Gaithersburg, Maryland) according to the manufacturer’s
guidelines. The vessels were homogenized, and the RNA
was isolated using RNeasy Mini Kit (Qiagen) (5,6). The
gene expression of interest was determined using RT-PCR
analysis (6). Table 1 lists the primers used. Samples from
different animals were not pooled. Typically, 1–2.5 μg of
RNA can be obtained from the graft vein, which can be
used to perform RT-PCR for 10 genes.
Immunohistochemistry
Ki-67 staining was used to determine cellular proli-
feration, and α-SMA staining was used to determine
smooth muscle cell density on sections removed from the
outﬂow vein at the different time points. The following
antibodies were used: mouse monoclonal antibody for
Ki-67 (1:400; Dako, Carpentaria, California) or rabbit
polyclonal antibody to mouse for α-SMA (1:400;
Abcam, Cambridge, Massachusetts) (7,10). Quantiﬁca-
tion was performed as described later on (7,10).Table 1 . Polymerase Chain Reaction Primers Used in Current Study
Gene Sequence
Vegf-A 50-atgaagtgatcaagttcatgg-30 (sense)
50-ggatcttggacaaacaaatgc-30 (antisense)
Vegfr-1 50-tttccatttgatactcttac-30 (sense)
50-tcttagttgctttaccaggg-30 (antisense)
Mmp-2 50-agatcttcttcttcaaggaccggtt-30 (sense)
50-ggctggtcagtggcttggggta-30 (antisense)
Mmp-9 50-gtttttgatgctattgctgagatcca-30 (sense)
50-cccacatttgacgtccagagaagaa-30 (antisense
18S 50-agctaggaataatggaatag-30 (sense)
50-aatcaagaacgaaagtcggag-30 (antisense)Hypoxyprobe Staining of LV-shRNA-Vegf-
A and Scrambled shRNA Vegf-A
Transduced Vessels
Hypoxyprobe-1 was used to assess hypoxic changes after
treatment in the graft vein. Each mouse was injected
with 60 mg/kg Hypoxyprobe-1 via intraperitoneal deliv-
ery; 30 minutes after injection, mice were sacriﬁced, and
outﬂow veins were dissected and ﬁxed as speciﬁed for
histologic analysis. Following the manufacturer’s direc-
tions, 4-μm-thick parafﬁn-embedded sections were
stained with the anti-Hypoxyprobe-1 antibody (7,10).
Terminal Deoxynucleotidyl Transferase
dUTP Nick End Labeling Staining of LV-
shRNA-Vegf-A and Scrambled shRNA
Vegf-A Transduced Vessels
To assess apoptosis, terminal deoxynucleotidyl transferase
dUTP nick end labeling (TUNEL) staining was used on
parafﬁn-embedded sections from the outﬂow vein after LV-
shRNA-Vegf-A or control shRNA vessels according to the
manufacturer’s directions (DeadEnd Colorimetric TUNEL
System; Promega Corporation, Madison, Wisconsin) (7,10).
Picrosirius Red Staining of LV-shRNA-
Vegf-A and Scrambled shRNA Vegf-A
Transduced Vessels
To assess collagen deposition, picrosirius red staining
was performed on unstained sections from LV-shRNA-
Vegf-A and scrambled shRNA at different time points as
described elsewhere (7,10).
Morphometry and Image Analysis of
LV-shRNA-Vegf-A and Scrambled
shRNA Vegf-A Transduced Vessels
Morphometric analysis was performed as described
previously (12,13). Using an Axioplan-2 Microscope
(Zeiss, Oberkochen, Germany) equipped with a Neo-
Fluor 20/0.50 objective and Axiocam camera that
allows images to capture a minimum of 1,030  1,300
pixels, 4-μm sections stained with hematoxylin-eosinAmplicon Length Cycles
360 35
310 35
225 35
208 35
)
150 19
Figure 2. Kaplan-Meier estimates for patency between LV-
shRNA-Vegf-A and control shRNA transduced vessels. C ¼
control shRNA-treated vessels; LV ¼ LV-shRNA-Vegf-A–treated
vessels.
Table 2 . Patent and Occluded Vessels at Day 21, Day 28, and
Day 42 after AVF Placement
Time Patent Occluded Not Sure
Day 21 LV 3 4 5
Day 21 C 5 5 1
Day 28 LV 3 4 5
Day 28 C 2 6 3
Day 42 LV 4 8 0
Day 42 C 1 9 1
AVF ¼ arteriovenous ﬁstula; C ¼ control shRNA-treated
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used to measure the LVA, neointima, and media plus
adventitia area on the hematoxylin-eosin–stained sec-
tions. These different areas were manually traced (R.J.
or B.Y.). The KS-400 software has an automated
program that provides the area of the LVA, neointima,
and media plus adventitia along with the cellular density
(neointima and media plus adventitia). Staining quanti-
ﬁcation was performed as follows. For nuclear staining
(Ki-67 and TUNEL), the number of cells with nuclei
staining brown was determined divided by total number
of cells (brown þ blue) and multiplied by 100 (Ki-67
index and TUNEL index). For cytoplasmic staining (α-
SMA and Hypoxyprobe), the number of cells with
cytoplasm staining brown was divided by the total
number of cells and multiplied by 100 (α-SMA index
and Hypoxyprobe index).
Statistical Methods
Data are expressed as mean  SEM. Multiple compar-
isons were performed using a two-way analysis of
variance followed by Student t test with post hoc
Bonferroni correction. Kaplan-Meier survival model
was used to assess for differences in patency between
groups using a log-rank test. Signiﬁcant difference from
control value was indicated by *Po .05, **Po .01, Po
.001, or P o 0.0001. SAS version 9 (SAS Institute Inc,
Cary, North Carolina) was used for statistical analyses.vessels; LV ¼ LV-shRNA-Vegf-A–treated vessels.RESULTS
Surgical Outcomes
Placement of an AVF to connect the right carotid artery
to the ipsilateral jugular vein was performed in 72 mice,
with either 5  106 plaque-forming units of LV-shRNA-
Vegf-A (n = 36) or scrambled-shRNA (control, n = 36)
administered to the adventitia of the outﬂow vein where
the stenosis forms in this model (Fig 1c). Three mice died
after ﬁstula placement. Kaplan-Meier analysis was
performed to assess differences in patency between the
two groups, which demonstrated that the patency of LV-
shRNA-Vegf-A transduced vessels was improved com-
pared with control vessels (P ¼ .07) (Fig 2, Table 2).Second Administration of LV-shRNA-Vegf-
A to the Outﬂow Vein Is Associated with
an Increase in Average LVA with a
Decrease in Constrictive Remodeling
There was a 125% increase in the average LVA in the LV-
shRNA-Vegf-A transduced vessels compared with control
vessels at day 21 (34,545 μm2  2,208 vs 27,745 μm2 
1,874; average increase 125%; P ¼ .11) with a signiﬁcant
decrease in the mean LVA by day 28 (15,382 μm2 1,259
vs 30,435 μm2  4,081; average reduction 49%; P ¼
.0033), but not day 42 (20,665 μm2  3,343 vs 28,304 μm2 1,516; average reduction 27%; P ¼ .06) (Fig 3a, b).
There was no difference in the mean wall area between
the LV-shRNA-Vegf-A and control shRNA. Picrosirius
red staining was performed to qualitatively assess the
collagen 1 and 3 content. Yellow color signiﬁes collagen 1
or 3 staining (Fig 3a). Qualitatively, there was a decrease
in the collagen 1 or 3 staining by picrosirius red at day 21
in the LV-shRNA-Vegf-A transduced vessels compared
with control shRNA. There was no difference between
the two groups at day 28 or day 42.
Second Administration of LV-shRNA-Vegf-
A to the Outﬂow Vein Is Associated with a
Decrease in Cellular Proliferation
Using Ki-67 staining, by day 21, there was a signiﬁcant
reduction in the average Ki-67 index in the LV-shRNA-
Vegf-A transduced vessels compared with control vessels (30
 1.9 vs 36.5  1; average reduction 17%; Po .05). There
was no difference in the average Ki-67 index between the
two groups (day 28, P ¼ .28, and day 42, P ¼ .46) (Fig 4).
Second Administration of LV-shRNA-Vegf-
A to the Outﬂow Vein Is Associated with a
Decrease in α-SMA Expression
To assess for smooth muscle density, the outﬂow veins
from LV-shRNA-Vegf-A and control groups were
Figure 4. Cellular proliferation index is decreased in LV-shRNA-
Vegf-A transduced vessels compared with control shRNA trans-
duced vessels at day 21. Pooled data for the LV-shRNA-Vegf-A
and control shRNA groups at day 21, day 28, and day 42 are
shown. This ﬁgure demonstrates a signiﬁcant decrease in the
mean Ki-67 index in the LV-shRNA-Vegf-A transduced vessels
compared with control shRNA transduced vessels at day 21 after
ﬁrst administration. Two-way analysis of variance followed by
Student t test with post hoc Bonferroni correction was per-
formed. Signiﬁcant difference from control value was indicated
by **P o .01. Each bar shows mean  SEM of four animals per
group. C ¼ control shRNA-treated vessels; LV ¼ LV-shRNA-Vegf-
A–treated vessels.
Figure 5. α-SMA index is reduced in LV-shRNA-Vegf-A trans-
duced vessels compared with control shRNA-treated vessels at
day 21. Pooled data for the LV-shRNA-Vegf-A and control shRNA
groups at day 21, day 28, and day 42 are shown. This ﬁgure
demonstrates a signiﬁcant reduction in average α-SMA index in
the LV-shRNA-Vegf-A transduced vessels compared with control
shRNA-treated vessels at day 21. Two-way analysis of variance
followed by Student t test with post hoc Bonferroni correction
was performed. Signiﬁcant difference from control value was
indicated by *P o .05 or ##P o .0001. Each bar shows mean 
SEM of four to six animals per group. C ¼ control shRNA-treated
vessels; LV ¼ LV-shRNA-Vegf-A–treated vessels.
Figure 3. Hematoxylin-eosin with picrosirius red staining of the LV-shRNA-Vegf-A transduced vessels shows increased LVA with
decreased collagen expression. (a) Representative sections after hematoxylin-eosin staining (upper panel) and picrosirius red staining
(lower panel) at the venous stenosis of the LV-shRNA-Vegf-A and scrambled-VEGF-A transduced vessels at day 21 after the ﬁrst
administration. (b) Pooled data for the LV-shRNA-Vegf-A and control shRNA groups at day 21, day 28, and day 42 are shown.
Semiquantitative analysis for LVA shows an increase in the average LVA of LV-shRNA-Vegf-A transduced vessels compared with
control shRNA at day 21 after the ﬁrst administration. Two-way analysis of variance followed by Student t test with post hoc Bonferroni
correction was performed. Signiﬁcant difference from control value was indicated by **Po .01. Each bar shows mean  SEM of four to
six animals per group. C ¼ control shRNA-treated vessels; H&E ¼ hematoxylin-eosin; LV ¼ LV-shRNA-Vegf-A–treated vessels.
Janardhanan et al ’ JVIR580 ’ Repeat Adventitial Transductionstained for α-SMA (Fig 5). By day 21, the average α-
SMA index was signiﬁcantly reduced in the LV-shRNA-
Vegf-A transduced vessels compared with control vessels
(28.4  0.72 vs 39.9  2.83; average reduction 29%; Po
.0001), and it remained lower by day 28 (34.4  0.45 vs
40.7  1.82; average reduction 14%; P o .05). There
was no difference in average α-SMA staining between
the two groups at day 42 (P ¼ .59).Second Administration of LV-shRNA-Vegf-
A to the Outﬂow Vein Is Associated with a
Decrease in Hypoxyprobe Staining
The hypoxic regions in the outﬂow vein after treat-
ment with LV-shRNA-Vegf-A or control shRNA were
assessed using Hypoxyprobe staining (Fig 6). By day 21,
the average Hypoxyprobe index was signiﬁcantly
Figure 6. There is a signiﬁcant decrease in the Hypoxyprobe
index in LV-shRNA-Vegf-A transduced vessels compared with
control shRNA-treated vessels. Pooled data for the LV-shRNA-
Vegf-A and control shRNA groups at day 21, day 28, and day 42
are shown. This ﬁgure demonstrates a signiﬁcant reduction in
the average Hypoxyprobe index in the LV-shRNA-Vegf-A trans-
duced vessels compared with control shRNA-treated vessels at
day 21 after ﬁrst administration. Two-way analysis of variance
followed by Student t test with post hoc Bonferroni correction
was performed. Signiﬁcant difference from control value was
indicated by ##P o .0001. Each bar shows mean  SEM of four
to six animals per group. C ¼ control shRNA-treated vessels; LV
¼ LV-shRNA-Vegf-A–treated vessels.
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compared with control vessels (20.6  0.6 vs 29.4  0.6;
average reduction 31%; P o .001). By day 28 and day
42, there was no difference in the average Hypoxyprobe
index between the two groups (day 28, P ¼ .28, and day
42, P ¼ .46).
Second Administration of LV-shRNA-Vegf-
A to the Outﬂow Vein Does Not Increase
Apoptosis
Apoptosis was assessed using TUNEL staining performed
on sections removed from the outﬂow vein after trans-
duction with either LV-shRNA-Vegf-A or control shRNA
at day 21, day 28, and day 42. No difference was demon-
strated in average TUNEL index between the two groups
(day 21, P ¼ .24; day 28, P ¼ .63; and day 42, P ¼ .96).
Second Administration of LV-shRNA-Vegf-
A to the Outﬂow Vein Does Not Reduce
Gene Expression of Vegf-A, Mmp-2, or
Mmp-9
Gene expression for Vegf-A, Mmp-2, or Mmp-9 was
assessed using RT-PCR at day 21, day 28, and day 42 in
the two groups. There was no signiﬁcant difference in the
average gene expression of Vegf-A, Mmp-2, or Mmp-9
between the two groups.DISCUSSION
A previous study demonstrated that reducing Vegf-A gene
expression using shRNA that inhibits gene expression ofVegf-A at the time of AVF placement results in an increase
in the average LVA with a reduction in constrictive
remodeling. However, the authors observed a “catch-up”
phenomenon whereby the beneﬁt of the Vegf-A reduction
decreased by 14–28 days after delivery (7). The goal of the
present study was to determine if the beneﬁcial effects of
reducing Vegf-A could be extended by a second delivery of
shRNA. We observed that a second administration of LV-
shRNA-Vegf-A 2 weeks after the ﬁrst administration had
a modest improvement in LVA with a reduction in smooth
muscle cell density, proliferation, and Hypoxyprobe
staining. An increase in apoptosis or reduction in Vegf-A
and downstream gene products such as Mmp-2 and Mmp-
9 was not observed. These observations have implications
for the development of clinical therapies aimed at reducing
venous stenosis formation. For example, they provide
guidance for the development of a treatment with respect
to which part of the vessel wall to target (adventitia,
media, or endothelium), the duration of the treatment, and
timing of the treatment with relationship to the placement
of the AVF.
The mechanisms of failure of hemodialysis vascular
access are very complicated. Upstream mechanisms, such
as inﬂammation, shear stress, uremia, oxidative stress,
and others, have been implicated for contributing to the
vascular injury, which results in venous stenosis formation
(14–16). Multiple different cytokines—proliferative,
inﬂammatory, and angiogenic—have been associated
with hemodialysis vascular access failure, including
Vegf-A, Mmps, monocyte chemoattractant protein-1
(Mcp-1), and others (16–18). Recently, elastin deposition
within experimental ﬁstulae was described (19). Local
pharmaceutical delivery has been considered as a
potential strategy for treating vascular access failure
(9,10,20). Adventitial delivery of blood outgrowth endo-
thelial progenitor cells has been shown to alleviate
vascular injury associated with hemodialysis vascular
access grafts (21). In arterial injury, the presence of
local stem cells and circulating stem cells contributing to
the pathologic process is very well recognized, but the role
of these cells in VNH is less well recognized (22,23).
Finally, a recent study demonstrated that adventitial
delivery of human adipose-derived mesenchymal stem
cells to the outﬂow vein of murine AVF reduces VNH
mediated by a reduction in gene expression ofMcp-1 (24).
Many studies have demonstrated a role for differ-
entiation of ﬁbroblasts to myoﬁbroblasts and their
contribution to venous stenosis formation associated
with hemodialysis vascular access failure (12,25,26). In
the present study, we observed a reduction in smooth
muscle cell staining with anti-Vegf-A therapy is likely
due to a reduction in ﬁbroblast to myoﬁbroblast tran-
sition. In addition, we observed a decrease in prolifer-
ation as assessed using Ki-67 staining. This observation
is consistent with other studies demonstrating the Vegf-A
reduction results in a decrease in proliferation because
Vegf-A is necessary for cell survival and proliferation
Janardhanan et al ’ JVIR582 ’ Repeat Adventitial Transduction(27,28). A recent experimental study determined
different proliferation patterns using a pig model (29).
The investigators observed that within the ﬁrst week
of vascular access placement, there was increased
proliferation localized to the adventitia, and they
proposed that antiproliferative therapies during this
time period could potentially be a therapeutic target.
The reduction in cellular proliferation and α-SMA
expression implies that there was a reduction in Vegf-A
gene expression (7). As shown previously in many dif-
ferent studies, Vegf-A is necessary for cellular pro-
liferation (7). One reason for the lack of demonstration
of reduction in Vegf-A may be due to ﬁbrosis around
the vessel, and this ﬁbrosis may have decreased the
overall efﬁcacy of reducing Vegf-A to the vessel wall.
We have previously shown that adventitial delivery of
LV-shRNA-Vegf-A results in a “top down” effect by
reducing messenger RNA expression for Vegf-A that is
localized to the adventitia and media at day 3 and the
whole vessel wall by day 7 after transfection.
Alternatively, it is quite plausible that there was a
reduction in Vegf-A, which occurred at an earlier time
point, maybe a few days after delivery, which may
explain the reduced effects seen in the current study.
The Vegf-A-dependent phase for vascular injury has
been previously noted in experimental animal models of
arterial injury (30). It has been observed that there is a
Vegf-A-dependent phase for reducing stenosis formation
(30). When bevacizumab (Avastin) was used for a 4-
week period, similar results were observed with a catch-
up phenomenon occurring at the later time periods.
The present study has several limitations. First, a
larger second dose of LV-Vegf-A may have resulted in
further reduction in VNH. Second, the optimal timing
could be further modiﬁed so that an earlier dose may
have resulted in reduction in VNH. Third, targeting the
endothelium may have proven to be more beneﬁcial, as
has been described recently for arterial injury caused by
the metalloproteinase ADAMTS-7 (31). Finally, the
present study may have been underpowered, and
signiﬁcance may have been achieved with increasing
the number of animals in each group (30).
In conclusion, we propose that a second delivery of
the same dose of LV-shRNA-Vegf-A moderately
improves vascular remodeling associated with hemodial-
ysis AVFs. We postulate that this improvement is due in
part to a Vegf-A-dependent and Vegf-A-independent
phase of venous stenosis formation associated with
hemodialysis AVFs. Finally, we hypothesize that anti-
Vegf-A therapy needs to be used at the time of AVF
creation to decrease vascular injury and improve out-
comes in patients with hemodialysis AVFs.
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